Oncology Program Transfer, Responsibilities and Interim Program Management Sample Clauses

Oncology Program Transfer, Responsibilities and Interim Program Management. To the extent not otherwise provided in this Agreement, the Parties shall cooperate to fully transition the Oncology Program and all related activities to Licensee or its designee (the “Oncology Program Transfer”) within one hundred twenty (120) days after the Effective Date (the “Oncology Program Transfer Period”). Notwithstanding the foregoing, Licensee acknowledges and agrees that, subsequent to the Effective Date, it is and shall be solely responsible for the Oncology Program and all related activities, liabilities and obligations, including without limitation the active, ongoing development, clinical and regulatory activities and obligations related to Licensed Products in the Oncology Field that, as of the Effective Date, are being conducted and/or managed by or on behalf of Symphony (including by RRD International, LLC) (the “Ongoing Oncology Program Activities”). Symphony shall be responsible for the Oncology Program and all related activities, liabilities and obligations arising, or relating to periods, prior to the Effective Date, including without limitation development, clinical and regulatory activities and obligations related to Licensed Products in the Oncology Field arising, or relating to periods, prior to the Effective Date. During the Oncology Program Transfer Period, Symphony shall, on behalf of Licensee and at Licensee’s sole cost and expense, continue to conduct and/or manage (and/or have conducted and/or managed) the Oncology Program and all Ongoing Oncology Program Activities, consistent with past practice, to the extent that the Oncology Program and such Ongoing Oncology Program Activities have not been transferred to Licensee or its designee.
AutoNDA by SimpleDocs

Related to Oncology Program Transfer, Responsibilities and Interim Program Management

  • Development Responsibilities From and after the Effective Date, BMS shall assume sole responsibility for the Development of Compounds and Products in the Field in the Territory during the Term at its own cost and expense (including responsibility for all funding, resourcing and decision-making, subject to Sections 3.3 and 3.4), except with respect to the performance by Ambrx of the Research Program activities assigned to Ambrx pursuant to the Research Plan and as otherwise may be agreed upon by the Parties in writing. BMS, by itself or through its Affiliates and Sublicensees, shall use Diligent Efforts to Develop a Compound or Product in the Field in accordance with the Development Plan for the purpose of obtaining a Regulatory Approval in each Major Market. For clarity, it is understood and acknowledged that Diligent Efforts in the Development of Compounds and Products may include sequential implementation of Clinical Trials and/or intervals between Clinical Trials for data interpretation and clinical program planning and approval.

  • Customer Responsibilities (a) The Customer agrees to (i) promptly notify the Bank of any change that the Customer wishes to make to Exhibit B, (ii) promptly notify the Bank if any information contained in the Customer Information Sheet becomes inaccurate or untrue and (iii) indemnify the Bank for any losses resulting from the Customer's failure to adhere to the provisions of Subsection (a) of this Section 11.

  • Contractor Responsibilities It shall be Tenant’s responsibility to cause each of Tenant’s contractors and subcontractors to:

  • Monitoring Responsibilities The Custodian shall furnish annually to the Fund, during the month of June, information concerning the foreign sub-custodians employed by the Custodian. Such information shall be similar in kind and scope to that furnished to the Fund in connection with the initial approval of this Contract. In addition, the Custodian will promptly inform the Fund in the event that the Custodian learns of a material adverse change in the financial condition of a foreign sub-custodian or any material loss of the assets of the Fund or in the case of any foreign sub-custodian not the subject of an exemptive order from the Securities and Exchange Commission is notified by such foreign sub-custodian that there appears to be a substantial likelihood that its shareholders' equity will decline below $200 million (U.S. dollars or the equivalent thereof) or that its shareholders' equity has declined below $200 million (in each case computed in accordance with generally accepted U.S. accounting principles).

  • Specific Responsibilities In addition to its overall responsibility for monitoring and providing a forum to discuss and coordinate the Parties’ activities under this Agreement, the JSC shall in particular:

  • Client Responsibilities During the Term and subject to the provisions of this Schedule, Client shall at its expense (unless otherwise provided for herein) fulfill, or cause to be fulfilled by the Funds or otherwise, the Client obligations, if any, set forth in each Service Exhibit to this Schedule. Client hereby represents, warrants and covenants that the execution and delivery of this Schedule by Client and the performance of Client’s obligations under this Schedule have been duly authorized by all necessary action on the part of Client. Client must comply with the provisions of this Schedule. Client agrees that DST may seek relief from Client for any infringement of this Schedule such as, but not limited to, a material violation, breach, act of negligence or gross negligence, willful misconduct, misfeasance or malfeasance committed by Client or its officers, agents and assigns, in connection with Client’s obligations and responsibilities under this Schedule.

  • Collaboration Management Promptly after the Effective Date, each Party will appoint a person who will oversee day-to-day contact between the Parties for all matters related to the management of the Collaboration Activities in between meetings of the JSC and will have such other responsibilities as the Parties may agree in writing after the Effective Date. One person will be designated by Merck (the “Merck Program Director”) and one person will be designated by Moderna (the “Moderna Program Director,”) together will be the “Program Directors”. Each Party may replace its Program Director at any time by notice in writing to the other Party. Any Program Director may designate a substitute to temporarily perform the functions of that Program Director by written notice to the other Party. The initial Program Directors will be: For Moderna: [***] For Merck: [***]

  • ALPS’ Responsibilities In connection with its performance of TA Web, ALPS shall:

  • Information Systems Acquisition Development and Maintenance a. Client Data – Client Data will only be used by State Street for the purposes specified in this Agreement.

  • Joint Responsibilities In performing the Development Efforts, each party shall

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!